PharmaMedic Announces Expanded Medical Affairs Solutions to Boost Branded Sales from Existing Generic Portfolios
PharmaMedic helps generic manufacturers navigate a growing but challenging market. Click to learn more
#medicalaffairs
Tag
PMC strengthens collaboration with Healthcare Communication Agencies
At PharmaMedic Consultancy, we offer our specialised services to support healthcare communication agencies in navigating the complexities and challenges that come with delivering compliant and impactful messages in our ever-evolving industry.
5 Trends Shaping Medical Affairs in 2025 — Are You Ready?
As 2024 draws to a close, the question on everyone’s mind is — What’s next for medical affairs in 2025? With the healthcare landscape changing at an unprecedented pace, staying ahead means understanding the trends that will define the year ahead. From digital transformation to patient-centric strategies, these shifts are already reshaping the way medical affairs teams operate. Here’s what you need to know to stay prepared and relevant.
Building Better Care — NHS and Life Sciences Partnerships
A new report from The King’s Fund, NHS and Life Sciences Industry Partnerships: Collaborating to Improve Care, shows how working together can help the NHS improve care. The NHS is under pressure, and joining forces with the life sciences sector could bring in new ideas, tools, and support.
How Digital Opinion Leaders Are Shaping the Future of Medical Affairs
Healthcare is changing, and so is the way people influence it. Authority no longer stays locked in conference rooms or academic journals. Today, Digital Opinion Leaders (DOLs) drive key conversations online. These healthcare professionals shape debates that matter — bringing together peers, patients, and stakeholders in the digital spaces where they spend the most time. If your Medical Affairs strategy hasn’t tapped into the power of these digital voices, you might miss big opportunities to adapt, connect, and improve.
Groundbreaking £21.9M UK Platform Launched to Advance Cancer Immunotherapy
Cancer immunotherapy represents a remarkable advancement in medical science, offering hope for conditions once considered untreatable. While some patients experience life-changing results, a large number face limited success or significant side effects. This is particularly evident with melanoma treatments, where fewer than half of patients benefit from immunotherapy.
How Omnichannel KOL Engagement Drives Successful Medical Interactions
The pharmaceutical landscape is moving fast, and the importance of omnichannel engagement is becoming clear. Especially when it comes to reaching healthcare professionals (HCPs), and more specifically, Key Opinion Leaders (KOLs). These experts are at the forefront of medical advancements and reaching them in the right way can make all the difference. With the right omnichannel approach, you can build deeper, more meaningful relationships that cater to their unique preferences—helping them make decisions more efficiently in this ever-changing, complex field.
How-to Drive Patient Impact — Five Strategic Priorities for Medical Affairs
In today’s rapidly evolving healthcare landscape, Medical Affairs (MA) teams have taken on a pivotal role. They are no longer viewed as just support teams but are now essential in improving patient care, expanding access to treatments, and shaping the future of medicine. As healthcare becomes more complex, Medical Affairs is increasingly focusing on putting patients’ needs at the heart of every decision. By concentrating on five key areas, Medical Affairs can improve patient outcomes and strengthen the reputation of pharmaceutical companies.
Medical Affairs — Shaping the Future of Pharma and Biotech
Medical Affairs (MA) is increasingly becoming a key player in pharmaceutical and biotechnology organisations, standing alongside Research & Development (R&D) and commercial operations. Traditionally viewed as a support function, MA now plays a crucial role in shaping corporate strategy by integrating scientific expertise, patient insights, and clinical data into decision-making processes.